Navigation Links
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
Date:2/6/2013

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).  PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with hemophilia.

Currently, factor VIIa therapy is available only as an intravenous (IV) formulation, which can be onerous for patients.  The company will present new data at the EAHAD Congress showing that PROLOR's long-acting Factor VIIa-CTP has demonstrated the potential for subcutaneous (SC) administration in addition to standard IV dosing.  PROLOR researchers believe that a long-acting factor VIIa therapy that could be administered subcutaneously, using a simple injection, would allow children and adults with hemophilia to easily self-administer factor Vlla at home on a prophylactic basis, significantly improving their quality of life. 

Dr. Abraham Havron , CEO of PROLOR, commented, "We have previously presented data in animal models of hemophilia showing that Factor Vlla-CTP demonstrated superiority across key efficacy and safety parameters as compared to current factor VIIa therapy.  The potential for SC administration may represent a major competitive advantage for our long-acting Factor Vlla-CTP, and we expect to initiate a Phase II clinical trial in hemophilia patients in late 2013 or early 2014."

The data will be presented from 5:00-8:00pm local time on February 6, 2013 by Dr. Gili Hart , Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program.  The European Association fo
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
4. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
5. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
6. Puma Biotechnology Announces Completion of Private Placement
7. Animal Biotechnology - Technologies, Markets and Companies
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
11. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... The Workgroup for Electronic Data ... on the use of health IT to create ... of four new co-chairs to the organization’s Security ... ,     Peter Dumont, Senior Director – Privacy ... Deloitte Consulting LLP ,     Deidre Rodriguez, Director ...
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
... CUPERTINO, Calif., Jan. 31 In conjunction,with DURECT Corporation,s (Nasdaq: ... to listen to the conference call,that will be broadcast live over ... a.m. PST)., When: Wednesday, February 6, 2008 ... over the Internet -- Simply log on to http://www.durect.com, ...
... Jan. 31 American Oriental,Bioengineering Inc. (NYSE: ... pharmaceutical and nutraceutical products, today announced that,the company ... Medical Device Conference at the Grand Hyatt Hotel ... with institutional,investors and to present at 2:20 pm ...
... Chindex International,Inc. (Nasdaq: CHDX ) a leading ... in the People,s Republic of China,announced that it ... third,quarter ended December 31, 2007, on Friday, February ... a conference call on Friday,February 8, 2008 at ...
Cached Biology Technology:Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 3
(Date:10/25/2014)... Oct. 23, 2014 Research and Markets ... in Europe 2014-2018" report to their offering. ... assess individuals on the basis of their physical or ... both physiological traits such as fingerprints, face recognition, DNA, ... traits such as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/19/2014)... India over the last 30 years contributed only ... during that time, according to a new study ... ., "Energy access is fundamental to development: it ... education, communication, and health," says IIASA researcher Shonali ... energy access is widely agreed to be an ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Improved electricity access has little impact on climate change 2Sperm wars 2
... Toshisada Nishida is this year,s winner of the International ... research and contributions to primatology. The award was presented ... Scotland, on 7 August 2008. Nishida will also be ... ape and human evolution by the Leakey Foundation. He ...
... In a study on fetal alcohol syndrome, researchers were ... cells in a key area of the fetal brain ... acidic environment that alcohol produces. The cerebellum, the portion ... muscle coordination, is particularly vulnerable to injury from alcohol ...
... N.J., July 28 Ikaria Holdings, Inc., a ... the,U.S. Food and Drug Administration (FDA) has granted ... in the reduction of the incidence and,severity of ... organ,transplantation., Ralf Rosskamp, M.D., Executive Vice President ...
Cached Biology News:Springer editor Toshisada Nishida winner of 2 prestigious primatology awards 2Researchers block damage to fetal brain following maternal alcohol consumption 2Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants 2
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
... The Staccato Series of systems provide ... drug discovery , genomics, proteomics and drug ... three base configurations; Mini Workstation Series, Application ... Sciclone ELISA Station is a remarkably compact ...
Biology Products: